---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-24-000079"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:31:40.841976+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioVie's NE3107 shows PD Phase 2a non-motor symptom improvement; AD Phase 3 misses significance but biomarker gains

## Summary
- PD Phase 2a: NE3107 improved sleep/fatigue NMSS domain -2.4 pts vs placebo +1.0 (p=0.0159); correlated with motor improvements.
- PD: 26% of NE3107 patients had better morning motor scores vs 0% placebo (p=0.046); younger patients saw >6 point UPDRS advantage.
- AD Phase 3 missed significance per protocol; NE3107 showed 68% slowing of decline on CDR-SB and 26% on ADAS-COG-12.
- AD biomarkers: NE3107 associated with biological age deceleration -3.87 years (p=0.012), reduced fasting glucose and cholesterol.
- Principal component analysis suggests NE3107 may realign metabolic inflammation; data presented at AD/PD 2024 in Lisbon.

## SEC filing metadata
- accession: 0001520138-24-000079
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/0001520138-24-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013824000079/bivi-20240301_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-24-000079
- JSON: https://secwatch.observer/filing/0001520138-24-000079.json
- Plain text: https://secwatch.observer/filing/0001520138-24-000079.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.